AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACRX POWR Grades
- ACRX scores best on the Growth dimension, with a Growth rank ahead of 78.47% of US stocks.
- ACRX's strongest trending metric is Momentum; it's been moving down over the last 199 days.
- ACRX ranks lowest in Stability; there it ranks in the 1st percentile.
ACRX Stock Summary
- Acelrx Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.09% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.21 for Acelrx Pharmaceuticals Inc; that's greater than it is for merely 5.68% of US stocks.
- Revenue growth over the past 12 months for Acelrx Pharmaceuticals Inc comes in at 136.61%, a number that bests 95.94% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acelrx Pharmaceuticals Inc are ROYL, LJPC, MYOV, ITP, and QTT.
- ACRX's SEC filings can be seen here. And to visit Acelrx Pharmaceuticals Inc's official web site, go to www.acelrx.com.
ACRX Price Target
For more insight on analysts targets of ACRX, see our ACRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.21 | Average Broker Recommendation | 1.62 (Moderate Buy) |
ACRX Stock Price Chart Interactive Chart >
ACRX Price/Volume Stats
| Current price | $1.14 | 52-week high | $2.94 |
| Prev. close | $1.13 | 52-week low | $1.01 |
| Day low | $1.11 | Volume | 1,665,100 |
| Day high | $1.18 | Avg. volume | 4,928,675 |
| 50-day MA | $1.56 | Dividend yield | N/A |
| 200-day MA | $1.58 | Market Cap | 135.78M |
AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.
Latest ACRX News From Around the Web
Below are the latest news stories about Acelrx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACRX as an investment opportunity.
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseAcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical ProcedureAcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management. The study will evaluate … Full story available on Benzinga.com |
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical ProcedureAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at Montefiore Medical Center evaluating the perioperative use of DSUVIA (sufentanil sublingual tablet 30 mcg) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or for chronic pain management. |
AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital SettingsAcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management in the postoperative and emergency department settings in the Journal of Pain Research. |
AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap ConferenceAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that management will present an overview of AcelRx Pharmaceuticals, followed by a fireside chat with Dr. Pamela Palmer. The presentation will take place on March 24, 2021 at 9:25 AM EST / 6:25 AM PST, and the fireside chat will begin at 11:35 AM EST / 8:35 AM PST. |
ACRX Price Returns
| 1-mo | -18.57% |
| 3-mo | -58.84% |
| 6-mo | -21.38% |
| 1-year | -26.45% |
| 3-year | -54.40% |
| 5-year | -63.58% |
| YTD | -8.06% |
| 2020 | -41.23% |
| 2019 | -8.66% |
| 2018 | 14.07% |
| 2017 | -22.12% |
| 2016 | -32.47% |
Continue Researching ACRX
Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...